[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertrophic-cardiomyopathy-hcm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertrophic-cardiomyopathy-hcm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,47,75,97,126,149,171,193,221,244,265,288,316,338,357,376,397,424,468,493,521],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100644878","phase-2-aom0304-in-adult-patients-with-symptomatic-hypertrophic-cardiomyopathy-100644878",false,"NCT07675668","Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy","A Phase 2, Multi-Regional, Open-label, Three-Part Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy","Inclusion Criteria:\n\n1. Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent according to federal, local, and institutional guidelines before the first study-specific procedure.\n2. Men or women participants aged 18 to 70 years (both inclusive) at Screening.\n3. Documented diagnosed with HCM based on European Society of Cardiology\u002FAmerican College of Cardiology Foundation criteria: hypertrophied and non-dilated left ventricle in absence of other systemic or cardiac causes, with left ventricular wall thickness ≥ 15 mm at diagnosis or ≥ 13 mm with a positive family history of HCM, or a known gene mutation related to HCM.\n4. Participants who are already treated with β-blockers, verapamil, diltiazem, or ranolazine should have been on stable doses for at least 4 weeks prior to Day 1 and anticipate remaining on the same medication regimen during the study.\n5. Body weight must be ≥ 45 kg and body mass index 18 to 35 kg\u002Fm2 (both inclusive) at Screening.\n6. LVEF ≥ 60% at Screening.\n7. Symptomatic HCM defined as NYHA functional Class II or III at Screening.\n8. Part-specific requirements at Screening:\n\n   * Part 1: Post-Valsalva LVOT-G ≥ 30 mmHg and \\\u003C 50 mmHg.\n   * Part 2: Resting LVOT-G ≥ 50 mmHg or resting ≥ 30 mmHg with post-Valsalva ≥ 50 mmHg.\n   * Part 3: Resting\u002Fpost-Valsalva or exercise LVOT-G \\\u003C 30 mmHg with NT-proBNP \\> 300 pg\u002FmL.\n9. Have adequate acoustic windows for accurate TTEs.\n10. Female participants must not be pregnant or lactating and if sexually active, must be using 1 of the following acceptable contraceptive methods from the Screening through 3 months after the last dose of the study drug. Hormonal contraceptives are not considered highly effective contraceptive methods for this study. Acceptable contraceptive methods are listed as below.\n\n    * Double-barrier method (eg, vasectomy or male using a condom and female using a diaphragm or cervical cap).\n    * Barrier (eg, male using a condom) plus non-hormonal intrauterine device or intrauterine system.\n    * Females are surgically sterile for 6 months or postmenopausal for 2 years. Permanent sterilisation includes hysterectomy, bilateral oophorectomy, bilateral salpingectomy, and\u002For documented bilateral tubal occlusion at least 6 months prior to Screening.\n\n    Females are considered postmenopausal if they have had amenorrhea for at least 2 years or more following cessation of all exogenous hormonal treatments and follicle-stimulating hormone (FSH) levels are ≥ 40 IU\u002FL at Screening (confirmed by at least 2 separate occasions during Screening Period).\n11. Male participants with female partners (including postmenopausal partners) must agree to use highly effective contraceptive measures. from the Screening through 3 months after the last dose of study drug. Highly effective contraception is presented in Inclusion criterion #10.\n\n    As there may be a risk of drug being secreted in the ejaculate, male participants (including men who have had vasectomies) whose partners are currently pregnant, or not pregnant or capable of becoming pregnant, should use barrier methods for the duration of the study and 3 months following the last dose of study drug in order to prevent passing Aom0304 to the partner in the ejaculate.\n12. Male and female participants must agree to not donate sperm or ova after the first dose of study drug until at least 3 months following last dose of study drug.\n13. Must be able to complete the Dyspnoea Numeric Rating Scale (NRS) and the KCCQ per established guidelines.\n14. Participants must be able to safely undergo CPET at Baseline and follow-up.\n\nExclusion Criteria:\n\n1. Participants with clinically significant haematology or chemistry abnormalities at Screening, as determined by the Investigator, including but not limited to:\n\n   * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3 × upper limit of normal (ULN).\n   * Total bilirubin \\> 2 × ULN.\n   * Haemoglobin \\\u003C 9 g\u002FdL.\n   * Platelet count \\\u003C 100000\u002FµL.\n   * Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73m².\n2. Known hypersensitivity to Aom0304, or any of the components of the formulation of Aom0304, or alcohol.\n3. History of sustained ventricular tachyarrhythmia or cardiac arrest.\n4. Implanted cardioverter defibrillator (ICD) placement within 3 months prior to Screening or planned ICD placement during the study.\n5. History of myocardial diseases other than HCM, including but not limited to: myocarditis, ischemic cardiomyopathy, dilated cardiomyopathy, cardiac amyloidosis, restrictive cardiomyopathy, Takotsubo syndrome, arrhythmogenic right ventricular cardiomyopathy.\n6. Poor controlled hypertension, defined as systolic blood pressure (BP) ≥ 160 mmHg or diastolic BP ≥ 100 mmHg at Screening or Baseline despite stable antihypertensive therapy.\n7. Participants who have been treated with septal reduction therapy (surgical myectomy or percutaneous alcohol septal ablation) or have plans for either treatment during the study period.\n8. History of syncope with exercise within past 6 months prior to Screening.\n9. Active infection, defined as any acute bacterial, viral, or fungal infection of any organ system (eg, respiratory, urinary, gastrointestinal, skin\u002Fsoft tissue, cardiovascular, or central nervous system) requiring systemic antimicrobial therapy or considered to be clinically significant by the Investigator.\n10. Current or recent (within 3 months prior to Screening) treatment with cardiac myosin inhibitors (eg, mavacamten, aficamten).\n11. Persistent atrial fibrillation (AF), or paroxysmal AF with resting heart rate (HR) \\> 100 bpm within 1 year prior to Screening.\n12. Have QT interval corrected by Fridericia's (QTcF) formula \\> 500 ms, or any other ECG abnormality considered by the Investigator to pose a risk to participant safety (eg, second degree atrioventricular block type II).\n13. Aortic stenosis or fixed subaortic obstruction.\n14. History of left ventricular systolic dysfunction (LVEF \\\u003C 45%).\n15. History of obstructive coronary artery disease (stenosis of \\> 70% of luminal diameter or \\> 50% of luminal diameter with ischemic symptoms in one or more coronary arteries), documented history of myocardial infarction or stroke.\n16. History of malignancy of any type, with the following exceptions: in situ cervical cancer more than 5 years prior to Screening or surgically excised non-melanomatous skin cancers more than 2 years prior to Screening.\n17. Positive serologic test at Screening for infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).\n18. Participants with positive alcohol or drug screen results considered clinically significant or indicative of ongoing abuse, as judged by the Investigator.\n19. History or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the Investigator, would pose a risk to participants' safety or interfere with the study evaluation, procedures, or completion.\n20. Participated in a clinical trial where the participants received any investigational drug (or is currently using an investigational device) within 30 days prior to Screening, or at least 5 times the respective elimination half-life (whichever is longer).\n21. Current use of tobacco- or nicotine-containing products \\> 20 cigarettes\u002Fday or equivalent.\n22. Prior treatment with cardiotoxic agents such as doxorubicin or similar, or current treatment with antiarrhythmic drugs that have negative inotropic activity, eg, flecainide or propafenone.\n23. Unable to comply with the study restrictions\u002Frequirements, including the number of required visits to the clinical site.","ALL","18 Years","70 Years",{"count":20,"type":21},56,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is designed to characterise the safety, tolerability, efficacy, and PK of Aom0304 across oHCM and nHCM populations and to inform dose selection for future Phase 3 development. The main questions it aims to answer are:\n\n1. Which dose is safe and tolerant of Aom0304 in participants with HCM?\n2. Which dose is effective of 12 weeks of Aom0304 treatment in participants with oHCM or nHCM? Researchers will compare different doses of Aom0304 to see which works best. All participants will receive Aom0304, but at different dose levels depending on which cohort they joined.\n\nParticipants will:\n\n1. Undergo screening up to 28 days before enrollment to confirm eligibility\n2. Adjust dose every 2 weeks assessed by the Investigator according to predefined criteria at Titration Phase (Week 1 Day 1 to Week 8).\n3. Continuation of the last tolerated and effective dose; no further escalation is permitted at Maintenance Phase (Week 8 to Week 12).\n4. Study drug discontinued and follow up at Off-treatment Follow-up Period (at the end of Week 12 to Week 16).",[27,28,29],"Hypertrophic Cardiomyopathy (HCM)","Obstructive HCM (oHCM)","Non-obstructive HCM (nHCM)",[31,32,33,34],"Hypertrophic cardiomyopathy (HCM)","Aom0304","Left ventricular outflow tract gradient (LVOT-G)","Left ventricular ejection fraction (LVEF)","NOT_YET_RECRUITING","2026-06-23",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":21},"2026-10-01",{"date":43,"type":21},"2028-04-30",{"name":45,"class":46},"Amckaus PTY LTD.","INDUSTRY",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100608541","phase-3-la-hcm-study--rivaroxaban-for-antithrombotic-prevention-in-hypertrophic-cardiomyopathy-patients-with-abnormal-left-atrial-strain-100608541","NCT07202897","LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.","LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain: A Randomized Multicenter Trial","LA-HCM","Inclusion Criteria:\n\n1. 40 - 80 years of age\n2. 50 and 120 kg of weight\n3. In sinus rhythm\n4. Prior confirmed diagnosis of \"primary\" hypertrophic cardiomyopathy\n5. Left Atrial reservoir strain measured ≤20% (corelab confirmation)\n6. Signature of an informed consent\n7. Highly effective contraceptive methods for women of childbearing potential from at least 14 days prior to start treatment, throughout the study treatment period, and until at least 4 weeks after the last dose of study medication\n\nExclusion Criteria:\n\n1. Secondary hypertrophic cardiomyopathy (aortic stenosis, hypertension, amyloidosis and all phenocopies…)\n2. Signs of heart failure\n3. Hospitalization\n4. Uncontrolled blood pressure\n5. Creatinine clearance \\\u003C30 mL\u002Fmin (Cockcroft)\n6. Severe liver dysfunction, cirrhosis Child B or C\n7. Any anticoagulation therapy in the 15 days prior to enrollment\n8. Any cardiac surgery in the 30 days prior to enrollment\n9. Documented atrial arrhythmia\n10. Any major bleeding in the 90 days prior to enrollment\n11. Need to be on dual antiplatelet therapy (aspirin \\>100 mg daily and a P2Y12 inhibitor, i.e. clopidogrel, ticagrelor, prasugrel…).\n12. Contraindication for a brain magnetic resonance imaging exam\n13. Known hypersensitivity or others contraindications to Rivaroxaban (refer to contraindications)\n14. Ischemic stroke or intracranial hemorrhage in the 30 days prior to enrollment\n15. Active endocarditis at the time of enrollment\n16. Concomitant combined strong P-gp and CYP3A4 inducers or inhibitors\n17. Active cancer or life expectancy less than 3 years\n18. Non-compliant\n19. Participation in another interventional clinical trial\n20. Protected person (adults legally protected (under judicial protection, guardianship or supervision), person deprived of their liberty, pregnant woman, lactating woman or planning pregnancy during the study period and minor)\n21. Absence of coverage by a social security scheme","40 Years","80 Years",{"count":58,"type":21},532,[60],"PHASE3","Hypertrophic cardiomyopathy (HCM) is a common (\\> 1\u002F500 in the general adult population) genetically transmitted disease impacting markedly patients' lives from the early ages to the latest. The phenotype as the prognosis of HCM may greatly differ from one patient to another: most patients present no or few symptoms and a near-normal lifespan, while others are severely symptomatic. Paroxysmal, persistent or permanent atrial fibrillation (AF) is frequent in HCM, occurring in more than 20%-25% of patients and is often considered as an important turning point for the quality of life of these patients. AF decreases cardiac output and exercise tolerance, increases hospitalization rate, and markedly increase the risk of embolic stroke with the need for life-anticoagulation. It has been shown that stroke may precede AF discovery and that it may occur at young ages with devastation consequences. AF also may trigger sudden cardiac death.\n\nObservational studies have been conducted to search for parameters which correlate with the risk of AF (P wave duration and supra-ventricular burst on the Holter-ECG monitoring, L-wave morphology, degree of hypertrophy, clinical parameters-comorbidities, and size of the left atrium) with no real impact on clinical management. Left Atrial strain (LA-strain) has been recently demonstrated relevant (for instance our pilot work (for predicting stroke and\u002For AF (a cut-off of 15% is highly specific, 20% being the optimal cut-off). LA-strain (cut-off 20%) could be used for defining the patients that might require preventive anticoagulation therapy.\n\nA randomized clinical trial is needed to extend the use of anticoagulation therapy to patients in sinus rhythm but identified to be at risk for AF.\n\nOf note, it has been demonstrated that in this population, stroke occurred in 67% of the patients without any clinical atrial arrhythmia.",[27],"RECRUITING","2026-06-11",{"date":66,"type":39},"2026-06-12",{"date":68,"type":39},"2026-01-07",{"date":70,"type":21},"2033-01-07",{"name":72,"class":73},"Rennes University Hospital","OTHER",17,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100642432","a-real-world-hcm-cohort-trial-100642432","NCT07638033","A Real-world HCM-cohort Trial","A Multicenter, Prospective, Real-world Study on Hypertrophic Cardiomyopathy","Inclusion Criteria:\n\n1. Meet the clinical diagnostic criteria for HCM\\*;\n2. Patients who understand the purpose of this study, voluntarily participate in the trial and sign the informed consent form, have good compliance, and are willing to undergo clinical follow-up.\n\n   * Clinical diagnosis of HCM is defined as left ventricular wall thickness ≥15mm at any position during diastole by.echocardiography or CMR (≥13mm if there is a family history of HCM or positive cardiac genetic testing), and other secondary factors (such as severe hepertension, aortic stenosis) causing myocardial hypertrophy are excluded.\n\nExclusion Criteria:\n\n1. Metabolic syndrome or hypertrophic cardiomyopathy-like syndromes associated with left ventricular hypertrophy, such as amyloid cardiomyopathy, sarcoidosis, Fabry disease, Danon disease or Noonan syndrome;\n2. Severe systemic hypertension and\u002For severe aortic stenosis (\\\u003C1cm²);\n3. Comorbid malignant tumors;\n4. Comorbid with other end-stage diseases with an expected lifespan of less than 3 years;\n5. Comorbid with mental disorders;\n6. Currently participating in other clinical trials and not reaching the primary endpoint.",{"count":83,"type":21},3000,"3 Years","OBSERVATIONAL","Hypertrophic cardiomyopathy (HCM) is a genetically mediated myocardial disease predominantly caused by pathogenic mutations in sarcomeric protein genes and characterized by asymmetric left ventricular hypertrophy. Patients with HCM commonly present with dyspnea, chest pain, and exercise intolerance. Sudden cardiac death, progressive heart failure, and thromboembolic events remain the leading causes of mortality and morbidity, substantially impairing quality of life and increasing healthcare burden.\n\nDespite advances in understanding the pathophysiology, diagnosis, and management of HCM, significant challenges persist, including etiological heterogeneity and underdiagnosis. At present, dedicated and systematic HCM databases remain lacking in China. Establishing a nationally HCM cohort and disease-specific database is therefore of considerable importance. In alignment with the goals of the \"Healthy China 2030\" initiative and supported by advances in medical big data technologies.\n\nThis study aims to construct a comprehensive HCM cohort, evaluate contemporary diagnostic and therapeutic practices and patient prognosis, identify relevant risk factors, and ultimately improve the overall management of patients with HCM.",[27],"2026-06-04",{"date":90,"type":39},"2026-06-10",{"date":38,"type":21},{"date":93,"type":21},"2030-12-31",{"name":95,"class":73},"Xijing Hospital",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100640080","phase-4-mavacamten-to-aficamten-transition-in-patients-with-obstructive-hypertrophic-cardiomyopathy-100640080","NCT07600177","Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy","CMI-SWITCH","Inclusion Criteria:\n\n* Documented history of oHCM with documented resting and\u002For Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially.\n* Echo-derived LVEF ≥55% on mavacamten at the time of enrollment.\n* Patient willing to consent for the study and undergo the study procedures.\n\nExclusion Criteria:\n\n* Severe aortic stenosis or sub-aortic obstruction\n* Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM (eg, Noonan syndrome, Fabry disease, amyloidosis).\n* History of LVEF \\\u003C30%.\n* Paroxysmal atrial fibrillation (AF) with documented episode within 3 months.\n* Atrial fibrillation (paroxysmal or permanent) not on systemic anticoagulation.\n* Documented history of current obstructive coronary artery disease (\\> 70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction.","90 Years",{"count":106,"type":21},40,[108],"PHASE4","This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).",[27],[112,113,114,115],"aficamten","mavacamten","cardiac myosin inhibitor","CMI","2026-05-14",{"date":118,"type":39},"2026-05-20",{"date":120,"type":39},"2026-05-05",{"date":122,"type":21},"2027-03-15",{"name":124,"class":73},"Oregon Health and Science University",2,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":132,"enrollmentInfo":133,"targetDuration":135,"studyType":85,"phases":4,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":96},"100622305","multicentre-hypertrophic-cardiomyopathy-registry-100622305","NCT07381894","Multicentre Hypertrophic Cardiomyopathy Registry","Inclusion Criteria:\n\n* Confirmed diagnosis of Hypertrophic Cardiomyopathy (HCM) clinically and not solely explained by abnormal loading conditions (e.g., significant hypertension, valvular disease\n\nExclusion Criteria:\n\n* Participants who do not fulfil the imaging and clinical diagnostic criteria of HCM","99 Years",{"count":134,"type":21},2500,"5 Years","Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition, affecting approximately 1 in 500 people. It causes the heart muscle to thicken, which can lead to blockages in blood flow (left ventricular outflow tract obstruction), shortness of breath, and an increased risk of heart failure or sudden cardiac arrest.\n\nWhile standard treatments exist and new targeted medications (cardiac myosin inhibitors) have recently been approved, doctors still need better data to predict which treatments will work best for each individual patient. This national registry based in the UK is a secure database that collects health information from HCM patients across multiple NHS hospital sites in the UK over several years.\n\nParticipants in this study will have their routine health information collected from their medical records, including details from heart scans (echocardiograms and MRIs), blood tests, and genetic information. With this HCM registry, we aim to improve disease understanding and risk prediction, paving the way for more personalised treatment plans for the HCM community in the future",[27],[139],"hypertrophic cardiomyopathy","2026-04-27",{"date":142,"type":39},"2026-05-01",{"date":144,"type":39},"2026-04-01",{"date":146,"type":21},"2029-01-01",{"name":148,"class":73},"University of Manchester",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":156,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":96},"100627861","mechanisms-of-atrial-pathoelectrophysiology-in-hcm-100627861","NCT07454135","Mechanisms of Atrial Pathoelectrophysiology in HCM","MAP HCM","Inclusion Criteria:\n\n* Paroxysmal or persistent atrial fibrillation\n* Diagnosis of hypertrophic cardiomyopathy\n* Patient planning to proceed to atrial fibrillation ablation following clinical consultation\n* Age 18-80 years\n* Able and willing to provide written informed consent\n* Able and willing to comply with study follow up requirements\n\nExclusion Criteria:\n\n* Any clinical contra-indication to ablation\n* Any disease limiting life expectancy to \\\u003C1 year\n* Potential participant currently pregnant or breast feeding\n* Contraindication to MRI including renal dysfunction (eGFR\\\u003C30ml\u002Fmin)\n* Unable to understand verbal or written explanations given in English",{"count":106,"type":21},"This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual.\n\nResearchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them.\n\nThe information from this study may help improve future treatments for people who have both HCM and AF.",[27,159],"Atrial Fibrillation (AF)",[139,161],"atrial fibrillation","2026-03-31",{"date":164,"type":39},"2026-04-06",{"date":166,"type":21},"2026-03-08",{"date":168,"type":21},"2027-09-30",{"name":170,"class":73},"Guy's and St Thomas' NHS Foundation Trust",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":177,"enrollmentInfo":178,"targetDuration":180,"studyType":85,"phases":4,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":192},"100597098","hcmr-re-imaging-study-100597098","NCT07054073","HCMR Re-Imaging Study","Inclusion Criteria:\n\nPatients in the original HCMR cohort with:\n\n1. Obstructive HCM\n\n   * Males and females between 18 and 65 years of age\n   * BMI \\\u003C 35 kg\u002Fm2\n   * LVOT-G at entry as follows:\n\n   Resting gradient ≥50 mmHg OR Resting gradient ≥30 mmHg and \\\u003C50 mmHg with post-Valsalva LVOT-G ≥50 mmHg\n\n   • NYHA Class II or III or\n2. Non-obstructive HCM\n\n   * Same criteria as above except resting LVOT-G is \\\u003C30mmHg and post-Valsalva gradient \\\u003C50mm Hg\n   * BMI \\\u003C40kg\u002Fm2\n   * Elevated NT-proBNP \\> 300 pg\u002FmL at the time of enrollment\n   * LVEF ≥55%\n\nExclusion Criteria:\n\n* Paroxysmal atrial fibrillation or flutter documented prior to entry.\n* Paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) ≤6 months prior to entry. (This exclusion does not apply if atrial fibrillation has been treated with anticoagulation and adequately rate-controlled for \\>6 months.)\n* History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to entry.\n* Pregnancy due to potential risk of gadolinium to the fetus\n* Patients with a pacemaker that are pacer-dependent as they cannot undergo MRI","65 Years",{"count":179,"type":21},314,"1 Day","This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM). HCM causes the heart muscle to become thick, which can make the heart stiff and harder to work properly. It can also affect the heart's electrical system.\n\nThis study is looking to enroll patients that were previously part of a research project called \"HCMR - Novel Predictors of Outcome in Hypertrophic Cardiomyopathy.\" The results of that study are still being reviewed, but they might show that people who had a substance called Gadolinium (MRI contrast or dye) collected in their heart muscle may have a higher risk for heart problems, including sudden cardiac death. This is called \"late gadolinium enhancement\" (LGE). This study is aiming to do follow-up imaging on those patients to better understand how LGE affects people with HCM.",[27],"2026-03-17",{"date":185,"type":39},"2026-03-18",{"date":187,"type":21},"2026-03-30",{"date":189,"type":21},"2027-07",{"name":191,"class":73},"Christopher Kramer",8,{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":199,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":96},"100628629","phase-1-application-of-68gaga-ni-fapi-04-petct-imaging-in-fibroblast-activation-protein-related-diseases-100628629","NCT07464132","Application of [68Ga]Ga-NI-FAPI-04 PET\u002FCT Imaging in Fibroblast Activation Protein Related Diseases","Inclusion Criteria:\n\n* 1: 18-85 years old\n\n  2: Tumor patients can undergo surgery or biopsy to obtain pathological diagnosis\n\n  3: Ability to understand and sign informed consent forms\n\n  4: Expected survival period exceeding 6 months and able to receive follow-up\n\n  5: Healthy volunteers without chronic medical history of hypertension, diabetes, coronary heart disease, kidney disease, tumor, etc\n\nExclusion Criteria:\n\n* 1: Pregnant or lactating women\n\n  2: Patients allergic to research drug ingredients\n\n  3: Patients with severe liver and kidney dysfunction (blood creatinine levels exceeding 159 μ mol\u002FL)\n\n  4: Patients who participate in other clinical trials and interfere with the results of this study\n\n  5: Patients with severe illness who cannot cooperate with the examination",true,"85 Years",{"count":202,"type":21},30,[204,24],"PHASE1","The purpose of this study is to conduct clinical research on \\[68Ga\\] Ga-NI-FAPI-04 PET\u002FCT imaging and further investigate its diagnostic value in fibroblast activation related diseases.",[207,208,209,210,27,211],"Tumor","Cardiovascular Diseases","Pulmonary Fibrosis","Rheumatic Immune Diseases Involving Large Blood Vessels","Other Hypoxic and Fibroblast Activated Diseases","2026-03-09",{"date":214,"type":39},"2026-03-11",{"date":216,"type":39},"2025-12-17",{"date":218,"type":21},"2027-06-17",{"name":220,"class":73},"Peking Union Medical College Hospital",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":228,"targetDuration":230,"studyType":85,"phases":4,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":96},"100619427","retrospective-natural-history-study-of-rasopathy-associated-cardiomyopathy-ras-cm-100619427","NCT07344480","Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)","RAS-CM","Inclusion Criteria:\n\n* Molecular genetic diagnosis of a RASopathy (i.e., a pathogenic or likely pathogenic variant in one of the RAS-MAPK pathway genes identified, irrespective of when performed)\n* Imaging diagnosis of myocardial hypertrophy (echocardiography) showing a maximal end-diastolic wall thickness of greater than normal (z-score \\> 2) with or without outflow tract obstruction\n* Admitted to hospital between 01\u002F01\u002F2015 and 06\u002F30\u002F2019 for congestive heart failure\\* or developing progressive congestive heart failure during any hospital stay within first 6 months of life\\*\\*\n\n  * Ross score calculated from medical history and physical examination notes in the absence of any other reason prompting hospital admission (e.g., elective procedure, other organ dysfunction, etc.); \\*\\*: defined by Ross Score greater than 2\n\nExclusion Criteria:\n\n* Receiving mechanistic Target of Rapamycin Inhibitor (mTOR inhibitor) and\u002For Mitogen-Activated Protein Kinase Kinase Inhibitor (MEK inhibitors)\n* Inability to identify or retrospectively calculate the patient´s Ross Score within the first six months of life",{"count":229,"type":21},100,"12 Months","RASopathy-associated hypertrophic cardiomyopathy (RAS-CM) is a disease with high morbidity and high mortality if presenting during infancy. Targeted therapies have shown significant activity in preclinical models and case reports. Drugs that target the underlying cause of this disease are now developed in cancer patients. Conducting randomized trials is not possible in severely ill infants with RAS-CM. Existing historical controls from older eras are not sufficient as external controls to support drug development as they lack critical clinical and genetic information to allow comparison with the cohort planned for future clinical trials.\n\nThe purpose of this investigator-initiated retrospective natural history study is to collect clinical information and genetic information in patients with RAS-CM. The first goal is to establish a data set that meets regulatory requirements for the use as external control data in a future clinical trial, composing non-randomized, single-arm, open-label study cohorts. The second goal is to obtain natural history information that supports the selection of secondary exploratory endpoints chosen in a clinical trial.",[27,233,234],"Heart Failure","RASopathy","2026-02-16",{"date":237,"type":39},"2026-02-18",{"date":239,"type":39},"2025-06-17",{"date":241,"type":21},"2026-12-31",{"name":243,"class":73},"Deutsches Herzzentrum Muenchen",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":132,"enrollmentInfo":251,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":253,"conditions":254,"keywords":255,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":96},"100624345","precision-pharmacogenetics-and-genotype-class-based-prediction-of-mavacamten-response-in-obstructive-hypertrophic-cardiomyopathy-100624345","NCT07408427","Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy","PRO-Gene Mava","Inclusion Criteria:\n\n* Participants above the age of 18 years, with a confirmed diagnosis of oHCM, not solely explained by abnormal loading conditions (e.g. significant hypertension, valvular disease).\n\nExclusion Criteria:\n\n* HCM phenocopies (e.g., amyloid, Fabry's disease)\n* Prior septal reduction therapy (within 6 months)\n* Contraindications to mavacamten (e.g., baseline LVEF \\\u003C 55%, pregnancy, uncontrolled heart failure)",{"count":252,"type":21},140,"This research study, aims to understand why a specific heart medication called mavacamten works better for some people with hypertrophic cardiomyopathy (HCM) than for others. We believe the answer might be in our genes.\n\nThe study focuses on two key areas:\n\n1. The specific gene causing HCM:The study will investigate whether the type of gene causing the condition in a person influences how well mavacamten works for them.\n2. Each individual carry a certain gene that helps metabolise and process medication (otherwise known as pharmacogenetics). Our research will closely examine a gene called CYP2C19 to see if a person's natural processing speed (slow, normal, or fast) affects the medicine's performance. The study will also look for rare genetic variations that standard tests might miss.",[27],[139,256],"pharmacogenetics","2026-02-06",{"date":259,"type":39},"2026-02-13",{"date":261,"type":21},"2026-06",{"date":263,"type":21},"2029-12",{"name":148,"class":73},{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":96},"100600912","phase-4-the-therapeutic-value-of-mavacamten-in-hypertrophic-cardiomyopathy-with-mid-to-apical-left-ventricular-obstruction-100600912","NCT07103655","The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction","The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction: A Prospective, Interventional, Real-World Clinical Study.","BRAVE-HCM","Inclusion Criteria:\n\n* Patients diagnosed with HCM according to the 2023 Chinese Guidelines for the Diagnosis and Treatment of Adult Hypertrophic Cardiomyopathy, meeting one of the following:\n\n  1. Left ventricular wall thickness ≥15 mm at end-diastole in any segment as assessed by echocardiography or cardiac magnetic resonance imaging (CMR);\n  2. Left ventricular wall thickness ≥13 mm in individuals with a confirmed pathogenic gene mutation or in genetically affected family members;\n  3. Exclusion of other cardiovascular, systemic, or metabolic disorders that may cause ventricular hypertrophy.\n\n     * Symptomatic non-outflow tract obstructive HCM patients (meeting criterion a and at least one of b or c):\n\n  \u003C!-- -->\n\n  1. Presence of clinical symptoms such as dyspnea, chest pain, dizziness, palpitations, or syncope, with New York Heart Association (NYHA) functional class II-III;\n  2. Maximal pressure gradient (PGmax) \\>30 mmHg in the mid-ventricle under resting or Valsalva maneuver as assessed by echocardiography;\n  3. PGmax \\>30 mmHg in the apical region under resting or Valsalva maneuver on echocardiography.\n\n     ③Ability to provide written informed consent (ICF) and any required privacy authorization prior to study enrollment.\n\n     Exclusion Criteria:\n\n     \\-\n* Obstructive hypertrophic cardiomyopathy (HCM), defined as a maximal left ventricular outflow tract pressure gradient (LVOT-PGmax) ≥30 mmHg at rest and during the Valsalva maneuver on echocardiography;\n\n  * Maximal right ventricular outflow tract pressure gradient (RVOT-PGmax) ≥16 mmHg at rest; ③ Left ventricular ejection fraction (LVEF) \\\u003C50% on echocardiography;\n\n    * Uncontrolled primary hypertension;\n\n      * Moderate or severe aortic valve stenosis and\u002For primary mitral valve disease with severe mitral regurgitation; ⑥ Known infiltrative or storage disorders mimicking the HCM phenotype (e.g., Fabry disease, cardiac amyloidosis); ⑦ Presence of severe infections, hepatic dysfunction, renal impairment, or other serious conditions significantly affecting life expectancy.","75 Years",{"count":275,"type":21},132,[108],"This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-to-apical left ventricular obstruction.",[27],"2026-01-19",{"date":281,"type":39},"2026-01-21",{"date":283,"type":21},"2026-01-01",{"date":285,"type":21},"2027-01-01",{"name":287,"class":73},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":296,"conditions":297,"keywords":304,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":96},"100620597","multimodal-analysis-of-endomyocardial-biopsies-100620597","NCT07359690","Multimodal Analysis of Endomyocardial Biopsies","Inclusion Criteria:\n\n* Patients aged \\>18 years with a clinical indication for endomyocardial biopsy.\n* Patients capable of providing informed consent who have signed the consent form for participation in the study.\n\nExclusion Criteria:\n\n* Patients without a clinical indication for endomyocardial biopsy (EMB).\n* Pregnant individuals.\n* Patients incapable of providing informed consent.\n* Women of childbearing potential who are not using adequate contraception.",{"count":295,"type":21},216,"The goal of this observational study is to pursue a multimodal approach to identify the molecular signatures and immune signalling molecules of various myocardial diseases and thereby contribute to improving diagnosis and therapy.\n\nThe main aim is:\n\n-Identification of molecular profiles (e.g., proteome, lipidome, metabolome) and immune signalling profiles that are specifically associated with different myocardial diseases and the post-heart transplantation course.\n\nParticipants already receiving an endomyocardial biopsy as part of their regular medical care will be enrolled. An additional biopsy sample will be taken for the above mentioned research.",[298,299,27,300,301,302,303],"Heart Transplantation","Dilated Cardiomyopathy (DCM)","Myocarditis, Pericarditis","Amyloidosis Cardiac","Cardiomyopathies","Sarcoidosis of the Heart",[305,306],"Endomyocardial biopsy","Multimodal analysis","2026-01-15",{"date":309,"type":39},"2026-01-22",{"date":311,"type":39},"2025-10-27",{"date":313,"type":21},"2028-09-30",{"name":315,"class":73},"University Hospital, Essen",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":199,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":96},"100620209","the-application-of-t1-mapping-in-real-world-100620209","NCT07354646","The Application of T1 Mapping in Real-World","The Landscape of T1 Mapping for Disease Profiling in a Real-World Cohort","Inclusion Criteria:\n\n1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines.\n2. Specific disease categories include:\n\n   * Cardiomyopathies (HCM, DCM, RCM, ACM)\n   * Infiltrative disorders (cardiac amyloidosis, Fabry disease)\n   * Inflammatory conditions (acute\u002Fchronic myocarditis)\n   * Ischemic heart disease (acute\u002Fchronic MI)\n   * Valvular heart disease (aortic stenosis)\n   * Arrhythmic conditions (atrial fibrillation)\n   * Metabolic disorders (iron-overload)\n   * Neoplastic conditions (cardiac tumors)\n   * Congenital heart disease\n   * Post-transplant evaluation\n3. All diagnoses must be confirmed using established guideline-based criteria:\n\n   * Echocardiographic parameters meeting disease-specific cutoffs\n   * Cardiac MRI findings consistent with current consensus criteria\n   * Laboratory biomarkers supporting respective diagnoses\n   * Histopathological confirmation when clinically indicated\n\nExclusion Criteria:\n\n* Presence of multiple cardiomyopathy diseases or risk factors simultaneously\n* Contraindications to CMR examination\n* Poor image quality precluding accurate T1 mapping analysis\n* Incomplete clinical data for definitive diagnosis confirmation\n* Pregnancy or lactation\n* Inability to provide informed consent",{"count":324,"type":21},2000,"The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are:\n\nWhat are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler \"native T1\" measurement (without contrast dye) instead of the more complex \"ECV\" measurement (which requires contrast dye) for diagnosis?\n\nPatients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping",[327,27,299,328,329],"Myocardial Infarction (MI)","Arrhythmogenic Cardiomyopathy","Myocarditis","2026-01-12",{"date":281,"type":39},{"date":333,"type":39},"2020-03-01",{"date":335,"type":21},"2026-12-01",{"name":337,"class":73},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":132,"enrollmentInfo":345,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":347,"conditions":348,"keywords":349,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":4},"100618526","myocardial-energetic-restoration-in-the-treatment-of-obstructive-hypertrophic-cardiomyopathy-100618526","NCT07332767","Myocardial Energetic Restoration in the Treatment of Obstructive Hypertrophic Cardiomyopathy","MERIT HCM","Inclusion Criteria:\n\n* at least 18 years of age and\n* Have a confirmed diagnosis of oHCM that is not solely explained by abnormal loading conditions such as significant hypertension or valvular disease\n* Qualify for mavacamten therapy by exhibiting a peak Left Ventricular Outflow Tract (LVOT) gradient of ≥ 50mmHg at rest or with provocation, New York Heart Association (NYHA) functional class II or III symptoms, and a baseline Left Ventricular Ejection Fraction (LVEF) of ≥ 55%\n\nExclusion Criteria:\n\n* HCM phenocopies such as cardiac amyloidosis or Fabry's disease\n* Undergone a septal reduction therapy (myectomy or ablation) within the preceding 6 months\n* Any contraindications to mavacamten (e.g., baseline LVEF \\\u003C 55%, pregnancy\u002Fbreastfeeding)\n* Inability to safely undergo a cardiac MRI, such as having non-compatible metal implants or severe claustrophobia",{"count":346,"type":21},20,"Hypertrophic Cardiomyopathy (HCM) is the most common inherited heart condition, where the heart muscles can thicken to the point of obstructing blood flow out of the heart. This condition is associated with a chronic state of energy loss in the heart muscle.\n\nTill more recently, a new class of medication (cardiac myosin inhibitors) have been introduced to directly target the heart muscle proteins (sarcomeres) to reduce the strength of contraction and relieve obstruction of blood flow out of the heart. While clinical trials have shown this class of medication significantly improves physical capacity and patient symptoms, it is still unclear, based on small scale published studies, where this improvement is achieved by restoring the fundamental energy balance within the heart.\n\nOur research study aims to answer this question and prove mechanistic insights of the use of this class of medication in the HCM population with blood flow obstruction (otherwise known as obstructive HCM) by using a specialised non-invasive MRI technique which accurately measures the heart energy score (specifically known as the PCr\u002FATP ratio) in each participant. Our objective is to determine how a patient with obstructive HCM have their energy scores affected, and improve over time with this medication therapy. If positive, this finding could establish the use of PCr\u002FATP ratio as a crucial, objective biomarker for monitoring therapeutic response and informing personalised dosing strategies for patient in the future.",[27],[139],"2025-12-29",{"date":330,"type":39},{"date":353,"type":21},"2026-04-30",{"date":355,"type":21},"2028-04",{"name":148,"class":73},{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":199,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":375,"locationsCount":96},"100613178","ai-enabled-diagnosis-and-prognosis-of-hypertrophic-cardiomyopathy-100613178","NCT07263204","AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy","Precision Diagnosis and Prognostic Prediction of Hypertrophic Cardiomyopathy Using Artificial Intelligence: A Multicenter Study","Inclusion Criteria:\n\n1. Adults aged ≥ 18 years.\n2. HCM cohort: Adults diagnosed with hypertrophic cardiomyopathy in accordance with the \\*2023 Chinese Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy in Adults\\*.\n3. HCM phenocopy cohort: Adults with an LV wall thickness ≥ 13 mm at any site on echocardiography.\n4. Healthy-control cohort: Adults with no history of cardiac disease and no evidence of myocardial hypertrophy on echocardiography.\n\nExclusion Criteria:\n\nPatients from whom analyzable ECG data cannot be obtained.",{"count":365,"type":21},15000,"By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic subtypes-while simultaneously differentiating HCM from hypertensive heart disease, aortic stenosis, and other phenocopy disorders.",[27,368],"Left Ventricular Hypertrophy","2025-11-23",{"date":371,"type":39},"2025-12-04",{"date":373,"type":39},"2025-01-01",{"date":241,"type":21},{"name":287,"class":73},{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":385,"conditions":386,"keywords":387,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":96},"100575698","a-real-world-study-on-hypertrophic-cardiomyopathy-in-chinese-population-100575698","NCT06775665","A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population","Clinical Characteristics and Real-World Outcomes of Chinese Patients With Hypertrophic Cardiomyopathy: A Prospective Cohort Study","HCM","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent (ICF) and any required privacy authorization before the start of the study.\n2. Aged ≥18 years at the time of signing the written informed consent.\n3. Diagnosed with hypertrophic cardiomyopathy (HCM) according to the 2023 Guideline for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy, meeting the following criteria:\n\n   1. Left ventricular wall thickness ≥15 mm in any segment at end-diastole, as assessed by echocardiography or cardiac magnetic resonance imaging (MRI).\n   2. Left ventricular wall thickness ≥13 mm in individuals with a positive pathogenic gene test or those identified as members of a genetically affected family.\n   3. Exclusion of other cardiovascular diseases or systemic\u002Fmetabolic diseases causing ventricular wall thickening.\n\nExclusion Criteria:\n\n1. Uncontrolled primary hypertension.\n2. Moderate or severe aortic valve stenosis and\u002For primary mitral valve disease with severe mitral regurgitation.\n3. Confirmed infiltrative or storage diseases with a phenotype resembling hypertrophic cardiomyopathy (e.g., Fabry disease, amyloidosis).\n4. Expected life expectancy \\\u003C1 years.\n5. Severe infections, liver failure, renal failure, or other life-threatening conditions.",{"count":83,"type":21},"This study is a prospective cohort study aimed at exploring the baseline characteristics and treatment patterns of the Chinese population with hypertrophic cardiomyopathy (HCM) in real-world settings. The objective is to assess the real-world treatment approaches and longitudinal outcomes in this population.",[27],[139,388],"real-world study","2025-05-25",{"date":391,"type":39},"2025-05-30",{"date":393,"type":21},"2026-06-01",{"date":395,"type":21},"2032-06-01",{"name":287,"class":73},{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":406,"briefSummary":408,"conditions":409,"keywords":413,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":96},"100587966","large-language-models-to-improve-the-quality-of-care-of-cardiology-patients-100587966","NCT06935253","Large Language Models To Improve the Quality of Care of Cardiology Patients","Towards Bridging Generalists to Subspecialists With Large Language Models","Inclusion Criteria:\n\n* Board certified or board eligible Cardiologist.\n\nExclusion Criteria:\n\n* Not currently practicing clinically",{"count":405,"type":21},12,[407],"NA","This study evaluates the impact of large language models (LLMs) versus traditional decision support tools on clinical decision-making in cardiology. General cardiologists will be randomized to manage real patient cases from a cardiovascular genetic cardiomyopathy clinic, with or without AI assistance. Each case will be assessed by two cardiologists, and their responses will be graded by blinded subspecialty experts using a standardized evaluation rubric.",[27,410,411,412],"Cardiomyopathy","Genetic Disease","Cardiology",[414,412],"Large language models","2025-05-13",{"date":417,"type":39},"2025-05-15",{"date":419,"type":39},"2025-01-10",{"date":421,"type":21},"2025-12",{"name":423,"class":73},"Stanford University",{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":16,"minAge":432,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":435,"conditions":436,"keywords":449,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":467},"100578603","characterization-of-patients-with-cardiomyopathy-to-identify-critical-patients-candidates-for-cardiac-transplantation-100578603","NCT06813443","Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation","Clinical, Instrumental, and Molecular (Circulating and Tissue microRNAs) Characterization of Patients With Cardiomyopathy to Identify Critical Patients With Severe Organ Failure to be Candidates for Cardiac Transplantation","CMPMIRNA","Inclusion Criteria:\n\n* Patients diagnosed with CMP according to current international guidelines\n* Age ≥ 12 years at the time of diagnosis\n* Obtaining informed consent from the patient and the parent or legal guardian (in the case of patients aged \\\u003C 18 years)\n\nExclusion Criteria:\n\n* none","12 Years",{"count":434,"type":21},700,"The study aims to identify new diagnostic and prognostic markers for CMP that can help predict disease progression. In particular, the study will focus on microRNAs (miRNAs) and spatial transcriptomics, which are emerging techniques that may provide insights into the underlying disease mechanisms. By understanding these markers, the investigators hope to improve the way the investigators diagnose and manage CMP, particularly in terms of predicting progression to heart failure or heart transplantation.\n\nThe study will evaluate patients with hypertrophic cardiomyopathy (e.g., sarcomeric forms, Anderson-Fabry disease, AL, and TTR cardiac amyloidosis), dilated cardiomyopathy and arrhythmogenic cardiomyopathy. These patients will undergo clinical evaluations, including ECG, echocardiograms, CMR, biopsy analysis, and genetic testing, as well as molecular studies such as transcriptomics and miRNA analysis. This comprehensive approach aims to identify potential new biomarkers for diagnosing and predicting the disease course.",[302,301,437,328,27,438,439,440,441,442,298,443,444,445,446,447,448],"Fabry Disease","Laminopathies","Dystrophia Myotonica","Mitochondrial Cardiomyopathy","Dilated Cardiomyopathy","Sudden Cardiac Death","Glycogen Storage Disease","Infiltrative Cardiomyopathy","Cardiac Magnetic Resonance Imaging","Electrocardiogram","Micro RNA","Echocardiogram",[450,451,452,139,453,454,455,456,457],"cardiomyopathy","cardiac amyloidosis","Fabry disease","dilated cardiomyopathy","sudden cardiac death","arrhythmogenic cardiomyopathy","heart failure","heart transplantation","2025-02-03",{"date":460,"type":39},"2025-02-07",{"date":462,"type":39},"2023-02-13",{"date":464,"type":21},"2027-12-14",{"name":466,"class":73},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",3,{"id":469,"slug":470,"hasResults":11,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":273,"enrollmentInfo":476,"targetDuration":4,"studyType":22,"phases":478,"briefSummary":479,"conditions":480,"keywords":483,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":491,"locationsCount":96},"100577162","early-identification-and-treatment-of-rare-cardiomyopathy-cohorts-100577162","NCT06794710","Early Identification and Treatment of Rare Cardiomyopathy Cohorts","Early Identification and Treatment of Rare Myocardium by Multimodal Imaging (EARLY-MYO-RARE)","EARLY-MYO-RARE","Inclusion Criteria:\n\n* Age 18-75 years old.\n* Patients preliminarily diagnosed with heart failure and scheduled to receive drug therapy after being evaluated by cardiology departments.\n* No history of structural heart disease, and the Framingham score \\<5 (for patients with the Framingham score ≥5, coronary artery disease will be excluded by coronary angiography\u002Fcoronary CT\u002Fexercise platelet).\n* Creatinine clearance ≥50ml\u002Fmin (Cockcroft-Gault formula).\n* LVEF ≥50% assessed by Echocardiography.\n* QT interval \\< 470 ms.\n* Providing written informed consent.\n\nExclusion Criteria:\n\n* Presence of acute\u002Fchronic renal impairment (GFR \\<50\u002Fml\u002Fmin\u002F1.73m2).\n* History of cardiovascular disease such as confirmed coronary artery disease, valvular disease, cardiomyopathy, congenital heart disease, and heart failure.\n* Presence of contraindications to CMR.",{"count":477,"type":21},300,[407],"This study aims to further develop an imaging-guided cohort of rare cardiomyopathies based on the existing database. The investigators will standardize the construction of a cohort that integrates a clinical data repository, serum biobank, myocardial tissue bank, and imaging database. In the current cohort, the investigators will systematically screen for biomarkers indicative of pathological changes in challenging cardiomyopathies. Multidimensional data will be integrated to establish and optimize a heart failure risk assessment model, which will then be validated in a prospective cohort. The effectiveness of the model in assessing different risk groups will be evaluated, with the goal of achieving precise prevention of heart failure from the source.",[27,299,481,482],"Metabolic Cardiomyopathy","Restrictive Cardiomyopathy",[484],"rare cardiomyopathy, cardiac multimodal imaging, myocardial impairment","2025-01-21",{"date":487,"type":39},"2025-01-27",{"date":489,"type":21},"2025-02-01",{"date":168,"type":21},{"name":492,"class":73},"RenJi Hospital",{"id":494,"slug":495,"hasResults":11,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":199,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":503,"conditions":504,"keywords":508,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":4},"100573590","ai-enabled-screening-and-diagnosis-of-cardiomyopathies-using-coronary-cta-100573590","NCT06748261","AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA","Artificial Intelligence-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary Computer Tomography Angiography","Atlantis","Cardiomyopathy cohort:\n\n* Inclusion Criteria:\n\n  1. A clinical diagnosis of cardiomyopathies, including hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, cardiac amyloidosis, myocarditis, arrhythmogenic right ventricular cardiomyopathy, and coronary artery disease\u002Fischemic heart disease.\n  2. At least one CCTA before surgery or implantable device treatment.\n* Exclusion Criteria:\n\n  1. No recorded diagnosis of cardiomyopathy or undetermined type of cardiomyopathy.\n  2. A clinical diagnosis of secondary cardiac abnormalities due to other organic or systemic diseases.\n  3. Surgery or implantable device treatment before CCTA examination.\n\nControl cohort:\n\n* Inclusion Criteria: participants with at least one CCTA examination.\n* Exclusion Criteria: clinical diagnosis of cardiovascular diseases (including cardiomyopathy, history of myocardial infarction, history of cardiac surgery, stent implantation, ICD implantation and so on) or secondary cardiac abnormalities due to systemic diseases.",{"count":502,"type":21},5000,"The goal of this observational and diagnostic study is to develop and validate an artificial intelligence assisted approach for coronary computer tomography angiography-(CCTA)-based screening and diagnosis of cardiomyopathies in patients with suspected coronary artery diseases. This study aims to develop a computerized CCTA interpretation using artificial intelligence for multi-label classification task to assist cardiomyopathy diagnosis in the clinical workflow.",[208,27,299,482,505,506,507,329,302],"Amyloid Cardiomyopathy","Ischemic Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy",[509,302,510,511],"Cardiac computer tomography angiography","Artificial intelligence","Diagnosis","2024-12-23",{"date":514,"type":39},"2024-12-27",{"date":516,"type":21},"2024-12-30",{"date":518,"type":21},"2025-12-30",{"name":520,"class":73},"Shanghai Zhongshan Hospital",{"id":522,"slug":523,"hasResults":11,"nctId":524,"briefTitle":525,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":528,"targetDuration":529,"studyType":85,"phases":4,"briefSummary":530,"conditions":531,"keywords":544,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":96},"100562769","multimodal-and-multidisciplinary-approach-to-optimize-diagnostic-prognostic-and-therapeutic-management-of-patients-with-non-ischemic-cardiomyopathies-and-arrhythmogenic-inflammatory-phenotypes-a-multicenter-observational-retrospective-and-prospective-registry-study-100562769","NCT06607471","Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.","AINICM","Inclusion Criteria:\n\n* Written informed consent. For pediatric patients, consent will be obtained by parents, according to the laws applicable in each of the participating countries.\n* Clinical suspicion of NICM, and\u002For proven diagnosis of any NICM and\u002For genotype consistent with any NICM.\n\nNICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic\u002Fautoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.\n\nExclusion Criteria:\n\n* Absent informed consent.\n* Proven diagnosis of cardiac disease alternative to NICM.\n* Lack of diagnostic workup suitable for diagnosing NICM, detecting arrhythmias, or detecting M-Infl.\n* For patients retrospectively enrolled: lack of active status of follow-up at the enrolling center.",{"count":365,"type":21},"30 Years","Non-ischemic cardiomyopathies (NICM) represent a heterogeneous group of pathologies characterized by absence of obstructive disease of the epicardial coronary vessels and distinct structural and functional changes of the myocardium. The main identified forms include dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic cardiomyopathy proper (ACM). More recently, further forms of cardiomyopathy have been described, less common and not uniquely classifiable, including: uncompressed myocardium (LVNC), peripartum cardiomyopathy (PPCM), structural correlates of arrhythmogenic mitral valve prolapse (AMVP), Anderson-Fabry disease (AFD), NICM associated with multi- system neuromuscular or autoimmune diseases, lysosomal diseases, glycogenosis, mitochondrial cytopathies and canal diseases with structural substrates. Finally, there are \"overlap\" forms, characterized by the sharing in the same subject of characteristic aspects of two or more of the above- mentioned diseases; and of the \"undefined\" forms, which to date do not reach the diagnostic criteria for any of the above-mentioned diseases.\n\nTo the best of current knowledge, there are two points discovered in scientific research, namely the description of the arrhythmogenic and \"inflammatory\" phenotypes in a broad sense, which are summarized here with the acronym AINICM. In detail:\n\n1. Arrhythmic manifestations account for the arrhythmogenic component of AINICM, which is not limited to ACM proper. In fact, most of the above diseases have a non-arrhythmic clinical presentation and a prevailing tendency to evolve towards a picture of cardiovascular decompensation. Although sudden arrhythmic death has been described throughout the spectrum of AINICM, early arrhythmic manifestations of such diseases have an unknown prevalence, an uncertain association with different disease genotypes and phenotypes, and still uncertain predictivity of long-term arrhythmic risk. At the same time, optimal diagnostic and therapeutic pathways in arrhythmias associated with AINICM are still being studied.\n2. Myocardial inflammation (M-Infl) accounts for the inflammatory component of AINICM, and has recently been described in association with many AINICM on a genetic basis, including undefined and arrhythmic forms. The data is of high interest not only in the diagnostic, but also in prognostic and therapeutic field. In fact, on the one hand the presence of M-Infl seems to have a physio- pathological role in AINICM; on the other, as already known in myocarditis, the optimal therapeutic paths of arrhythmias may differ in patients with and without M-Infl; in particular, also in the light of the preliminary data available in adult and paediatric AINICM, the inflammatory forms are expected to respond better to immunosuppressive therapy, the arrhythmogenic ones to an ablative therapy with frequent need of implantation of cardiac devices.\n\nBased on the clinical presentation, NICM patients will be divided into arrhythmic (AINICM) and non-arrhythmic patients as study and control groups , respectively. The AINICM group will include presentation with ventricular fibrillation (VF), either sustained or non-sustained ventricular tachycardia (VT; NSVT), frequent premature ventricular complexes (PVC), supraventricular arrhythmias (SVA) and bradyarrhythmias (BA). Clinical presentations other than arrhythmic, including chest pain and heart failure, will define the control group. In parallel, as shown in Figure 1, patients with any evidence of M-Infl will be compared with those showing no signs of M-Infl.",[532,299,27,482,533,534,535,536,537,538,539,540,541,542,543],"Non-ischemic Cardiomyopathy","Arrhythmogenic Cardiomyopathy (AC, ARVD\u002FC)","Left Ventricular Noncompaction","Arrhythmogenic Mitral Valve Prolapse","Peripartum Cardiomyopathy","Anderson-Fabry Disease","Arrhythmic and Inflammatory Non-ischemic Cardiomyopathy","Inflammatory (Non-Arrhythmic) Non-ischemic Cardiomyopathy","Nonischemic Cardiomyopathy Sensu Strictu (Non-inflammatory, Non-arrhythmic)","Major Ventricular Arrhythmias, I.e. Sustained Ventricular Tachycardia, Ventricular Fibrillation, or Appropriate Therapy of Cardiac Device (defibrillators)","Overlapping Phenotype","Undefined Phenotypes",[545,546,547,548,549,550,551,552,553,554,555,556,557,446,305,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,454],"Arrhythmogenic cardiomyopathy","Adverse event","Anderson-Fabry disease","Arrhythmic and Inflammatory Non-ischemic cardiomyopathy","Arrhythmogenic mitral valve prolapse","Anti tachycardia pacing","Bradiarrhythmias","Cardiac magnetic resonance","Cardiac resynchronization therapy with defibrillator","Computed tomography","Development Safety Update Report","Ethics Committee","Electroanatomical map","Good Clinical Practice","Hypertrophic cardiomyopathy","Implantable cardioverter defibrillator","Informed Consent Form","International Conference on Harmonization","Immunomodulatory therapy","Late gadolinium enhancement","Left ventricular ejection fraction","Left ventricular noncompaction","Last Visit of Last Subject","Myocardial inflammation","Non-ischemic cardiomyopathies","Positron emission tomography","Pacemaker","Peripartum cardiomyopathy","Premature ventricular complexes","Serious Adverse Event","Supraventricular arrhythmias","Ventricular arrhythmias","Ventricular fibrillation","Ventricular tachycardia (sustained)","2024-09-18",{"date":581,"type":39},"2024-09-23",{"date":583,"type":39},"2018-01-30",{"date":585,"type":21},"2035-12-31",{"name":587,"class":73},"Scientific Institute San Raffaele"]